Introduction
Diffuse large B-cell lymphoma (DLBCL) accounts for 25-35% of all new non-Hodgkin lymphoma diagnoses globally each year. 1, 2 Gene expression profiling (GEP) has identified at least three molecularly distinct DLBCL subtypes based on differential expression of genes involved in B-cell development, [3] [4] [5] [6] [7] [8] [9] [10] including activated B-cell-like (ABC), germinal center B-cell-like (GCB), and unclassified subtypes. GCB and non-GCB DLBCL subtypes can also be distinguished using immunohistochemistry (IHC) algorithms based on expression of markers including CD10, BCL6, and MUM-1;
these algorithms have demonstrated 71-93% concordance with GEP.
11-13
Clinical outcomes differ considerably between GCB and non-GCB DLBCL, 6, 8, [14] [15] [16] with overall survival (OS) significantly inferior in non-GCB patients (5-year OS rates: 16-64% vs 59-76% GCB). 3, 7, 17 Standard frontline treatment for DLBCL is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); 18, 19 however, outcomes with R-CHOP are inferior in non-GCB versus GCB DLBCL. 4, 13, [20] [21] [22] [23] More efficacious therapies targeting the molecular basis of non-GCB DLBCL are required.
The nuclear factor-κB (NF-κB) pathway is constitutively activated in non-GCB DLBCL, 3, 4, [24] [25] [26] [27] and represents a target for therapeutic intervention. The proteasome inhibitor bortezomib is a potent inhibitor of the transcriptional activity and nuclear translocation of NF-ĸB; 28-32 as such, bortezomib may have specific utility in non-GCB DLBCL. Bortezomib plus chemotherapy has demonstrated substantial activity in patients with previously untreated and relapsed DLBCL, 14,33,34 potentially overcoming the negative prognosis associated with non-GCB versus GCB disease.
14,33
Bortezomib plus R-CHOP appears to produce clinical benefit in non-GCB DLBCL. 33 However, due to overlapping toxicity between bortezomib and vincristine, a higherFor personal use only. on . by guest www.bloodjournal.org From 6 Offner Blood MS #BLOOD/2015/632430 than-expected rate of dose-limiting neurotoxicity has been observed with this combination. 35 In newly diagnosed mantle cell lymphoma (MCL), substitution of vincristine by bortezomib in the VR-CAP regimen has resulted in superior efficacy versus R-CHOP, while avoiding excessive neurotoxicity, 36 and VR-CAP has recently been approved for MCL by the US FDA.
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LYM-2034 was a multinational, randomized phase 2 study designed to evaluate VR-CAP versus R-CHOP in patients with previously untreated non-GCB DLBCL, as classified by central review using the Hans algorithm. 12 Here we report efficacy and safety results after 24.9 months' median follow-up from randomization. 
Study Design and Treatment
This randomized, open-label, phase 2 study was conducted at 57 centers in 18 countries worldwide between January 2010 and December 2011. Independent ethics committees or institutional review boards in the participating centers approved the study, which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Patients provided written informed consent.
During screening, patients were required to submit tumor biopsies for DLBCL subtyping. Formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks were Treatment was discontinued for progressive disease (PD) or relapse, unacceptable toxicity, >3 week delay in treatment due to insufficient recovery from toxicity, or patient withdrawal. Short-term follow-up visits to assess disease progression were required if treatment was discontinued before PD; these visits were completed every 6 weeks for 18 weeks, and then every 8 weeks thereafter until PD.
During short-term follow-up, patients were evaluated by physical examination and laboratory tests only. At any visit, if there was clinical evidence for, or suspicion of, PD, then a computed tomography (CT) and positron emission tomography (PET)
scan were performed at the investigator's discretion to document progression. All patients underwent long-term survival follow-up after documented PD or at the start of alternate antineoplastic therapy. Long-term follow-up visits were completed every 12 weeks until death.
Objectives
The primary objective was to determine the complete response (CR) rate with VR-CAP and R-CHOP. Secondary objectives were to determine: overall response rate (ORR; CR plus partial response [PR] rate); duration of response (DOR); time to next lymphoma therapy (TTNT); 1-and 2-year progression-free survival (PFS) and OS rates; safety of VR-CAP and R-CHOP; and concordance between IHC and GEP for non-GCB DLBCL subtyping.
GEP Confirmation of DLBCL Subtype
RNA samples extracted from FFPE tumor tissue provided to the central laboratory for IHC confirmation of non-GCB DLBCL subtype were also evaluated by GEP using quantitative RT-PCR. Tumor RNA was evaluated using SensationPlus™ FFPE 
Results

Patients
In total, 364 patients consented to DLBCL subtype screening and tumor samples from 342 patients were subtyped by IHC; 194 patients with non-GCB DLBCL were identified and of these, 26 did not meet the inclusion criteria and 4 were excluded for other reasons. Thus, 164 patients were randomized to VR-CAP (n = 84) or R-CHOP (n = 80). Figure 1 summarizes patient flow through the study.
Patient demographics and baseline disease characteristics were similar between the two arms, with a slight male preponderance in the R-CHOP group that was not statistically significant (Table 1) . Median age was 59.0 years (range 20-84), with 52 (32%) patients aged >65 years.
Treatment Exposure
Of 164 randomized patients, 2 in the VR-CAP arm and 1 in the R-CHOP arm did not receive any study drug; 161 patients were therefore included in the safety population. Treatment exposure is summarized in Table 2 . Seventy-one (87%) and 73 (92%) patients completed 6 cycles of treatment in the VR-CAP and R-CHOP arms, respectively. The remaining 11 (13%) and 6 (8%) patients, respectively, discontinued treatment before completing 6 cycles; reasons for discontinuation are noted in Figure 1 . Mean relative dose intensity was similar between the two regimens for common drugs. However, the rate of dose reduction for bortezomib in the VR-CAP arm (37%) was greater than that for vincristine in the R-CHOP arm (5%).
Efficacy
For personal use only. on April 2, 2017. by guest www.bloodjournal.org OR 0.21, P = .11) ( Table 3 ). In both arms, median time to response was 2.1 months.
There were no statistically significant differences between VR-CAP and R-CHOP with regard to durable (lasting ≥ 6 months) CR rate (61.8% vs 56.8%; OR 1.25, P = .52) or durable CR/PR rate (75.0% vs 78.4%; OR 0.84, P = .65) ( Table 3) . Fourteen (18.4%) and 15 (20.3%) patients had a DOR of <6 months in the VR-CAP and R-CHOP arms, respectively; of these patients, 7 and 11, respectively, were censored without PD. Subgroup analyses demonstrated no statistically significant differences between VR-CAP and R-CHOP in CR rate or ORR by baseline IPI score (Table S1 Figure 2 . For VR-CAP and R-CHOP, respectively, 2-year PFS rates were 76.2% and 77.1%, 2-year OS rates were 80.1% and 79.0%, and 2-year TTNT rates were 69.3% and 71.8% (Table 4 ). There were no significant between-arm differences in PFS (HR 1.12; P = .76), OS (HR 0.89; P = .75), or TTNT rates (HR 1.25; P = .49). Two-year PFS and OS rates appeared more favorable in patients with lower versus higher baseline IPI score; however, there were no overt between-arm differences (Table   S2 , Supplemental Data). Two-year PFS and OS rates appeared higher in patients with PET-negative versus PET-non-negative status (overall CR vs PR by combined CT+PET assessment) (Table S3 , Supplemental Data), an observation that was more notable in the VR-CAP arm; however, these results should be interpreted cautiously due to the low number of events.
Twenty-three (27%) patients in the VR-CAP arm and 19 (24%) in the R-CHOP arm received subsequent treatment. The most common agents received as subsequent therapy (VR-CAP vs R-CHOP) were rituximab (17% vs 11%), cytarabine (17% vs 10%), etoposide (16% vs 10%), dexamethasone (13% vs 6%), and cisplatin (12% vs 6%). Nine patients in the VR-CAP arm and 4 in the R-CHOP arm went on to receive high-dose therapy and autologous stem cell transplantation (HDT-ASCT) during subsequent therapy. For VR-CAP, details on CD34+ stem cell collection were available for 7 patients. After mobilization with G-CSF (n = 4) or chemotherapy (n = 3), CD34+ stem cell collection was successful in all 7 patients with a median yield of 6 x 10 6 cells/kg.
Concordance between IHC and GEP for non-GCB subtype classification
GEP confirmation of DLBCL subtype was performed in 103 patients randomized after IHC subtyping (VR-CAP: n = 53; R-CHOP: n = 50); in this population, the CR rate was 62.3% for VR-CAP (33/53) and 62.0% for R-CHOP (31/50). Ninety-one patients (n = 45 and n = 46, respectively) were confirmed to be non-GCB by GEP (88.3% concordance); in this population, the CR rate was 60.0% for VR-CAP (27/45) and 60.9% for R-CHOP (28/46). There were no significant between-arm differences in PFS (HR 0.91; P = .84) or OS (HR 1.08; P = .87) in patients with GEP-confirmed non-GCB DLBCL (Table S4 , Supplemental Data).
Safety
VR-CAP and R-CHOP had similar overall safety profiles (Table S5 , Supplemental Data). Rates of all-grade AEs (99% vs 100%), grade ≥ 3 AEs (88% vs 89%), serious AEs (SAEs) (38% vs 34%), treatment discontinuation due to AEs (7% vs 3%), and on-study deaths due to AEs (2% vs 5%) were similar for VR-CAP and R-CHOP. Table 5 summarizes the most common AEs in both treatment arms.
Focusing on the most common grade ≥ 3 AEs, VR-CAP was associated with neutropenia (78%), thrombocytopenia (37%), and leukopenia (22%), while with R-CHOP they were neutropenia (81%), leukopenia (23%), and febrile neutropenia (20%). Grade SAEs occurring in ≥ 5% of patients in either arm were febrile neutropenia (9% each), neutropenia (5% vs 6%), pyrexia (6% vs 0%), and pneumonia (5% vs 4%).
The most common AEs (>2% of patients in either arm) leading to dose reduction were neutropenia (21%), thrombocytopenia (11%), peripheral sensory neuropathy (10%), neuralgia (9%), and febrile neutropenia (6%) with VR-CAP, and neutropenia (14%), febrile neutropenia (4%), and hypertension (3%) with R-CHOP. The only AEs leading to discontinuation in >1 patient were PN NEC and neutropenia (each n = 2, all VR-CAP). Fifteen (18%) VR-CAP and 16 (20%) R-CHOP patients had died at data cutoff. There were 2 (2%) on-study deaths due to treatment-emergent AEs in the VR-CAP arm (cardiac arrest, upper gastrointestinal hemorrhage; each n = 1) and 3 (4%) in the R-CHOP arm (cardiac arrest, septic shock, and respiratory failure, each n = 1). 
Discussion
In this phase 2 randomized study, substituting bortezomib for vincristine in the standard R-CHOP regimen did not lead to a significant improvement in CR rate (primary endpoint), ORR, or durable response rate in patients with previously untreated, IHC-confirmed non-GCB DLBCL. In addition, 2-year PFS, TTNT, and OS rates did not differ significantly between the arms. Subsequent therapies were generally similar between the two treatment groups. Few patients received HDT-ASCT following VR-CAP or R-CHOP, reflecting common treatment practice for previously untreated DLBCL. 18, 19 At the time of this final analysis, PFS and OS data had not reached full maturity; however, findings from a recent report 44 indicate that 2-year PFS is a good surrogate marker for long-term outcomes in DLBCL, and therefore more extended follow-up is unlikely to reveal a survival benefit for VR-CAP.
The lack of efficacy improvement with VR-CAP in non-GCB DLBCL is in contrast with recent observations from a phase 3 study in newly diagnosed MCL, in which VR-CAP produced superior PFS, CR rates, time-to-progression, and TTNT as compared with R-CHOP.
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The outcomes observed with R-CHOP administered as six 21-day cycles (per common treatment practice at the time of study design -now increasingly administered as eight 21-day cycles or six 14-day cycles) 45-47 were largely consistent with previous studies of DLBCL. 4 To our knowledge, this is the first reported study to prospectively randomize patients with non-GCB DLBCL confirmed centrally prior to treatment. Only patients with non-GCB DLBCL classified by the Hans IHC method 12 were randomized to VR-CAP or R-CHOP therapy. The confirmation of non-GCB diagnosis prior to randomization requires two considerations in the interpretation of the data. Firstly, the concern for a delay in treatment caused by the central review procedure (only 5 days on average) may have excluded patients with the worst disease prognosis from being considered for participation in the trial, which may explain the relatively good outcomes in both arms of the study. Secondly, the IHC DLBCL subtype classification method was well accepted at the time of initiation of this study, but has subsequently become subject to discussion. It is possible that the lack of difference in efficacy between VR-CAP and R- 
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